This study proposes a model of computational consciousness for non-interacting agents. The phenomenon of interest was assumed as sequentially dependent on the cognitive tasks of sensation, perception, emotion, affection, attention, awareness, and consciousness. Starting from the Smart Sensing prodromal study, the cognitive layers associated with the processes of attention, awareness, and...
The psychedelic 5-HT2A receptor (5HT2AR) agonist psilocybin (or the active metabolite psilocin) has emerged as potential useful drug for various neuropsychiatric diseases, with a rapid onset of therapeutic activity. However, the mechanisms responsible for such effects remain incompletely characterized. We aimed to study in vitro pharmacological profile and in vivo acute mechanism of...
Rapastinel, a positive N-methyl-D-aspartate receptor (NMDAR) modulator with rapid-acting antidepressant properties, rescues memory deficits in rodents. We have previously reported that a single intravenous dose of rapastinel, significantly, but only transiently, prevented and rescued deficits in the novel object recognition (NOR) test, a measure of episodic memory, produced by acute or...
Schizophrenia ResearchAugust 25, 2022Olga Santesteban-Echarri, Lu Liu, Madeline Miller et al.
Cannabis use is more prevalent among youth at clinical high-risk (CHR) for psychosis than healthy controls (HC). There is mixed evidence as to whether cannabis use is associated with increased severity of attenuated psychotic symptoms (APS) or whether current cannabis use is associated with the transition to psychosis. This study aims to assess cannabis use differences between CHR youth and HC...
Abstract: This multi‐method study examined perspectives on mindfulness and coping strategies used by trauma‐exposed women experiencing homelessness (WEH), residing in a state‐funded residential drug treatment site in Southern California (United States). Questionnaires and in‐depth focus group interviews were utilised to examine traumatic experiences over the lifespan, probable‐posttraumatic...
Psychedelic or ecodelic medicines (e.g., psilocybin, ayahuasca, iboga) for the care and treatment of addiction, post‐traumatic stress disorder, cancer, cluster headaches, anxiety, and depression have surged to the forefront of discussions about mental health in the US, leading to the emergence of well‐capitalized biotech companies offering multimillion‐dollar IPOs. Venture capital website...
Abstract Background and objective Cannabis use during adolescence is common. Cannabis use and identity are thought to influence one another. This study aimed to examine what London-based adolescents (aged 16-17 years) think about cannabis use, its relationships with identity, and its benefits and harms. Method Three semi-structured focus groups interviews were conducted, two with adolescents...
Abstract Objective: Psychedelic-assisted therapies are emerging as safe and effective treatments for some psychological conditions including depression, anxiety, posttraumatic stress disorder, and substance use disorders. As ketamine therapy is already available in general medicine and 3,4 Methylenedioxymethamphetamine (MDMA) and psilocybin are in late-stage clinical trials, neuropsychologists...
New medicines containing classic hallucinogenic and entactogenic psychedelic substance are under development for various psychiatric and neurological disorders. Many of these, including psilocybin, lysergic acid diethylamide (LSD), and 3,4-methylenedioxymethamphetamine (MDMA) are Schedule I controlled substances of the United States Controlled Substances Act (US CSA), and similarly controlled...
Abstract Psilocybin and other serotonergic psychedelics have re-emerged as therapeutics for neuropsychiatric disorders, including addiction. Psilocybin induces long-lasting effects on behavior, likely due to its profound ability to alter consciousness and augment neural connectivity and plasticity. Impaired synaptic plasticity in obesity contributes to ‘addictive-like’ behaviors, including...